Request Samples

Patient Savings

Request a Rep

MOA

How QULIPTA® works

QULIPTA is specifically designed to prevent migraine attacks

CGRP levels increase during migraine attacks

While research into the exact mechanism that causes migraine is ongoing, CGRP is known to play a role.^4,5

When CGRP binds to CGRP receptors, it causes pain, inflammation, and vasodilation.^4-6

CGRP=calcitonin gene-related peptide.

QULIPTA is the only once-daily oral preventive CGRP receptor antagonist

QULIPTA® blocks CGRP protein from attaching to CGRP receptors

QULIPTA is the only once-daily oral preventive CGRP receptor antagonist

While some medications used to prevent migraine were initially developed to treat other conditions, QULIPTA was specifically designed to prevent migraine attacks. It works by directly targeting CGRP to block it from attaching to receptors.¹

Find out about QULIPTA dosing.

LEARN MORE

INDICATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS

Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

DRUG INTERACTIONS

Dose modifications are recommended when using the following:

Episodic migraine: Strong CYP3A4 inhibitors; CYP3A4 inducers; or OATP inhibitors
Chronic migraine: OATP inhibitors

In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.

USE IN SPECIFIC POPULATIONS

Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.

Avoid use in patients with severe hepatic impairment.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

US-QLP-230380

Please see full Prescribing Information.

This site is intended for U.S. healthcare professionals only.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

INDICATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

DRUG INTERACTIONS

Dose modifications are recommended when using the following:

Episodic migraine: Strong CYP3A4 inhibitors; CYP3A4 inducers; or OATP inhibitors
Chronic migraine: OATP inhibitors

In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.

USE IN SPECIFIC POPULATIONS

Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.

Avoid use in patients with severe hepatic impairment.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

US-QLP-230380